Global vaccine development efforts accelerate for hantavirus; multiple candidates in preclinical stages

A May 2026 CBC News article examines the current state of hantavirus vaccine development in response to a luxury cruise ship outbreak. Hantavirus infections lack curative treatments; medical management relies on supportive care such as oxygen therapy, ventilation, and fluid replacement. Researchers at multiple institutions—including the University of Saskatchewan, University of Bath's EnsiliTech, Moderna Inc., and the U.S. Army Medical Research Institute—are pursuing vaccine candidates. EnsiliTech reports developing an effective Hantaan virus antigen with positive rodent immunogenicity data and plans 3–4 year timeline to clinical trials. The Vaccine and Infectious Disease Organization targets Andes virus and Sin Nombre virus strains endemic to the Americas, with animal testing scheduled for summer 2026. Historically neglected due to low commercial interest and affected populations' limited purchasing power, vaccine development now depends on sustained political will and funding.